Bruker (NASDAQ:BRKR) Lowered to “Peer Perform” at Wolfe Research

Wolfe Research downgraded shares of Bruker (NASDAQ:BRKR) from an outperform rating to a peer perform rating in a report published on Monday, MarketBeat reports.

A number of other brokerages also recently weighed in on BRKR. TD Cowen reduced their price objective on shares of Bruker from $74.00 to $72.00 and set a hold rating for the company in a research note on Wednesday, August 7th. The Goldman Sachs Group reduced their price objective on shares of Bruker from $72.00 to $60.00 and set a sell rating for the company in a research note on Tuesday, July 9th. Wells Fargo & Company began coverage on shares of Bruker in a research note on Tuesday, August 27th. They set an overweight rating and a $78.00 price objective for the company. Jefferies Financial Group began coverage on shares of Bruker in a research note on Monday, June 3rd. They set a buy rating and a $85.00 price objective for the company. Finally, Citigroup reduced their price objective on shares of Bruker from $95.00 to $80.00 and set a buy rating for the company in a research note on Wednesday, July 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of Hold and an average target price of $81.40.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $65.80 on Monday. Bruker has a twelve month low of $53.79 and a twelve month high of $94.86. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $9.56 billion, a price-to-earnings ratio of 23.80, a PEG ratio of 2.43 and a beta of 1.18. The firm has a 50-day moving average of $65.36 and a two-hundred day moving average of $71.45.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.52. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company had revenue of $800.70 million during the quarter, compared to the consensus estimate of $799.44 million. During the same period in the prior year, the company earned $0.50 EPS. Bruker’s revenue was up 17.4% on a year-over-year basis. As a group, analysts expect that Bruker will post 2.61 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Monday, September 2nd were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date was Friday, August 30th. Bruker’s dividend payout ratio (DPR) is 7.27%.

Institutional Trading of Bruker

A number of hedge funds have recently made changes to their positions in the stock. Treasurer of the State of North Carolina increased its holdings in Bruker by 1.0% in the fourth quarter. Treasurer of the State of North Carolina now owns 48,608 shares of the medical research company’s stock worth $3,572,000 after buying an additional 468 shares during the last quarter. TFO Wealth Partners LLC increased its holdings in Bruker by 30,866.7% in the fourth quarter. TFO Wealth Partners LLC now owns 929 shares of the medical research company’s stock worth $68,000 after buying an additional 926 shares during the last quarter. KBC Group NV increased its holdings in Bruker by 6.6% in the fourth quarter. KBC Group NV now owns 38,051 shares of the medical research company’s stock worth $2,796,000 after buying an additional 2,356 shares during the last quarter. Public Employees Retirement Association of Colorado increased its holdings in Bruker by 925.8% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 362,035 shares of the medical research company’s stock worth $26,602,000 after buying an additional 326,741 shares during the last quarter. Finally, Epoch Investment Partners Inc. increased its holdings in Bruker by 248.4% in the fourth quarter. Epoch Investment Partners Inc. now owns 405,436 shares of the medical research company’s stock worth $29,791,000 after buying an additional 289,055 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.